The pennsylvania hemophilia program 1973–1978

M. Elaine Eyster, Jessica H. Lewis, Sandor S. Shapiro, Frances Gill, Mehdi Kajani, David Prager, Isaac Djerassi, Samuel Rice, Charles Lusch, Anne Keller

    Research output: Contribution to journalArticlepeer-review

    34 Scopus citations

    Abstract

    In Pennsylvania, the prevalence of hemophilia is one per 10,000 males. Factor VIII deficiency is five times more frequent than Factor IX deficiency, and 34% of the patients have no relatives affected with the disease. The mean age is 23 years old, and 50% of the patients are less than 20 years old. Approximately one‐third of the patients with Factor VIII deficiency and one fourth of the patients with Factor IX deficiency have levels of < 0.01 μ/ml. By clinical criteria, 55% of those with Factor VIII deficiency are severe compared to 45% of those with Factor IX deficiency. Factor VIII‐deficient patients are treated an average of 18 times per year compared to ten times per year for patients with Factor IX deficiency. Hemarthroses account for 70% of the hemorrhages treated and for 40% of the concentrate usage. Home therapy patients use an average of 45,950 Factor VIII units per year at a cost of $4,170 per patient and their use accounts for 60% of the total Factor VIII usage of 1.7 million units. Less than five days per patient per year are lost from school or work because of bleeding, and patients are hospitalized for bleeding an average of only two to three days per patient per year. Adverse immediate reactions to therapy are infrequent. Five percent of patients have persistence of the hepatitis B virus, and 7.5% have inhibitors. The mortality rate is 0.04% per year, with half of the deaths being hemophilia‐related.

    Original languageEnglish (US)
    Pages (from-to)277-286
    Number of pages10
    JournalAmerican Journal of Hematology
    Volume9
    Issue number3
    DOIs
    StatePublished - Nov 1980

    All Science Journal Classification (ASJC) codes

    • Hematology

    Fingerprint Dive into the research topics of 'The pennsylvania hemophilia program 1973–1978'. Together they form a unique fingerprint.

    Cite this